INS and glucose metabolism disease: ameliorates insulin sensitivity and glucose metabolism disorders by regulating the IRS1/PI3K/AKT signaling pathway and the expressions of its downstream targets GLUT4, FOXO1, and GSK3β (Jiang et al. 2023).